N
NovaBay Pharmaceuticals Inc
XBER:B9P
NovaBay Pharmaceuticals Inc
XBER:B9P
Price:
0.114
EUR
-11.63%
Market Closed
Market Cap:
€480.5k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
NovaBay Pharmaceuticals Inc
XBER:B9P
|
US |
|
V
|
Vontobel Holding AG
SIX:VONN
|
CH |
|
Surya Permata Andalan Tbk PT
IDX:NATO
|
ID |
|
D
|
Danieli & C Officine Meccaniche SpA
OTC:DNIYY
|
IT |
|
Pony Testing International Group Co Ltd
SZSE:300887
|
CN |
Balance Sheet
Balance Sheet Decomposition
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
Balance Sheet
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
5
|
2
|
10
|
3
|
3
|
7
|
12
|
8
|
5
|
3
|
|
| Cash Equivalents |
5
|
2
|
10
|
3
|
3
|
7
|
12
|
8
|
5
|
3
|
|
| Total Receivables |
0
|
1
|
2
|
4
|
3
|
1
|
1
|
2
|
2
|
1
|
|
| Accounts Receivables |
0
|
1
|
2
|
4
|
3
|
1
|
1
|
2
|
2
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
1
|
1
|
1
|
0
|
0
|
1
|
3
|
3
|
3
|
|
| Other Current Assets |
1
|
0
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
0
|
|
| Total Current Assets |
7
|
5
|
14
|
9
|
9
|
9
|
14
|
13
|
11
|
7
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
1
|
|
| Accumulated Depreciation |
2
|
2
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
2
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
|
| Total Assets |
8
N/A
|
5
-33%
|
15
+203%
|
10
-34%
|
9
-7%
|
11
+20%
|
15
+36%
|
24
+57%
|
16
-32%
|
9
-45%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
2
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
|
| Accrued Liabilities |
1
|
2
|
2
|
2
|
1
|
3
|
2
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
1
|
|
| Other Current Liabilities |
0
|
0
|
2
|
3
|
2
|
0
|
1
|
1
|
2
|
1
|
|
| Total Current Liabilities |
3
|
5
|
4
|
5
|
4
|
6
|
3
|
3
|
4
|
4
|
|
| Long-Term Debt |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
2
|
4
|
4
|
3
|
1
|
5
|
0
|
10
|
2
|
1
|
|
| Total Liabilities |
6
N/A
|
10
+79%
|
8
-19%
|
7
-10%
|
4
-41%
|
10
+132%
|
3
-72%
|
14
+373%
|
6
-58%
|
6
-2%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
2
|
|
| Retained Earnings |
72
|
91
|
104
|
111
|
115
|
125
|
136
|
142
|
158
|
175
|
|
| Additional Paid In Capital |
73
|
85
|
111
|
114
|
120
|
126
|
148
|
151
|
165
|
176
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
2
N/A
|
5
N/A
|
7
N/A
|
3
-64%
|
5
+91%
|
1
-80%
|
12
+1 170%
|
10
-17%
|
11
+4%
|
3
-69%
|
|
| Total Liabilities & Equity |
8
N/A
|
5
-33%
|
15
+203%
|
10
-34%
|
9
-7%
|
11
+20%
|
15
+36%
|
24
+57%
|
16
-32%
|
9
-45%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
0
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
